Co-treatment of wild‑type EGFR head and neck cancer cell lines with afatinib and cisplatin

Brands,Roman  C.; Müller‑Richter,Urs   D.A.; De Donno,Francesco; Seher,Axel; Mutzbauer,Grit; Linz,Christian; Kübler,Alexander  C.; Hartmann,Stefan

doi:10.3892/mmr.2016.4786

Co-treatment of wild‑type EGFR head and neck cancer cell lines with afatinib and cisplatin

Authors:
- Roman C. Brands
- Urs D.A. Müller‑Richter
- Francesco De Donno
- Axel Seher
- Grit Mutzbauer
- Christian Linz
- Alexander C. Kübler
- Stefan Hartmann
View Affiliations

Affiliations: Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, D‑97070 Würzburg, Germany, Institute of Pathology, University Würzburg, D‑97080 Würzburg, Germany
Published online on: January 14, 2016 https://doi.org/10.3892/mmr.2016.4786
Pages: 2338-2344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of head and neck squamous cell carcinoma (HNSCC) remains challenging. Non‑surgical approaches typically comprise radiotherapy and antineoplastic chemotherapy, of which platinum‑based agents are the most common. Similar to other malignancies, targeted therapies have an increasing role in the treatment of head and neck cancer. The overexpression of epidermal growth factor receptor (EGFR) is a useful target for specific therapeutic strategies. Resistance to EGFR‑directed therapies, including cetuximab, is partly mediated by the activation of alternative receptors and pathways. Therefore, other members of the ErbB family, including human epidermal growth factor receptor (HER)2 and HER4, may have important therapeutic roles. The aim of the present study was to investigate the efficacy of afatinib, an EGFR/HER2/HER4 tyrosine kinase inhibitor, in combination with cisplatin in HNSCC cell lines. The cisplatin concentration used was set at cell line‑specific half maximal inhibitory concentration values. Since the vast majority of head and neck cancers do not exhibit any EGFR tyrosine kinase domain mutations, five human EGFR wild‑type HNSCC cell lines were used in the present study. For statistical analyses, non‑parametric Mann‑Whitney tests were conducted. The present study detected a concentration‑dependent efficacy of afatinib. In three out of the five cell lines (PCI‑9, PCI‑52 and PCI‑68), 0.625 µM afatinib in combination with cisplatin exerted significant antiproliferative effects. In the two other cell lines (PCI‑1 and PCI‑13), significant effects were observed following treatment with ≥1.25 µM afatinib. Notably, compared with the findings of previous studies, cell lines (PCI-9 and PCI-52) less vulnerable to erlotinib or gefitinib were more vulnerable to the afatinib/cisplatin combination, and vice versa. Differences in the treatment success of erlotinib/gefitinib (targeting only EGFR) and afatinib (targeting EGFR, HER2 and HER4) may be explained by mutations in the EGFR. Therefore, afatinib treatment may be considered an important therapeutic option for patients failing cetuximab treatment. In addition, the present study demonstrated significant enhancement of platinum‑based therapies upon the addition of various afatinib concentrations. These results provide preclinical evidence to advocate further in vivo studies and clinical trials.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
3	Seiwert TY, Salama JK and Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 4:156–171. 2007. View Article : Google Scholar : PubMed/NCBI
4	Gupta S, Kong W, Peng Y, Miao Q and Mackillop WJ: Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
5	Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53:3579–3584. 1993.PubMed/NCBI
6	Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366:2–16. 2006. View Article : Google Scholar
7	Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 24:4170–4176. 2006. View Article : Google Scholar : PubMed/NCBI
8	Maurizi M, Scambia G, Benedetti Panici P, Ferrandina G, Almadori G, Paludetti G, De Vincenzo R, Distefano M, Brinchi D, Cadoni G, et al: EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance. Int J Cancer. 52:862–866. 1992. View Article : Google Scholar : PubMed/NCBI
9	Agulnik M: New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 29:2481–2491. 2012. View Article : Google Scholar : PubMed/NCBI
10	No authors listed. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol Ther. 5:340–342. 2006.PubMed/NCBI
11	Melosky B: Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. 4:2442014. View Article : Google Scholar
12	Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G and Zwierzina H: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer. 42:109–111. 2006. View Article : Google Scholar
13	Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 118:257–262. 2006. View Article : Google Scholar
14	Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, et al: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421. 2013. View Article : Google Scholar : PubMed/NCBI
15	Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM: Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
16	Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M and Krause M: Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol. 183:256–264. 2007. View Article : Google Scholar : PubMed/NCBI
17	Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E and Cohen EE: A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 25:1813–1820. 2014. View Article : Google Scholar : PubMed/NCBI
18	Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside TL: Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 49:5167–5175. 1989.PubMed/NCBI
19	Hartmann S, Kriegebaum U, Küchler N, Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success. J Craniomaxillofac Surg. 41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hartmann S, Seher A, Brands RC, Linz C, Lessner G, Böhm H, Kübler AC and Müller-Richter UD: Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells. J Craniomaxillofac Surg. 42:1322–1328. 2014. View Article : Google Scholar : PubMed/NCBI
21	Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, et al: Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 97:1185–1194. 2005. View Article : Google Scholar : PubMed/NCBI
22	Tardito S, Isella C, Medico E, Marchiò L, Bevilacqua E, Hatzoglou M, Bussolati O and Franchi-Gazzola R: The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 284:24306–24319. 2009. View Article : Google Scholar : PubMed/NCBI
23	Belcher R, Hayes K, Fedewa S and Chen AY: Current treatment of head and neck squamous cell cancer. J Surg Oncol. 110:551–574. 2014. View Article : Google Scholar : PubMed/NCBI
24	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
25	Vermorken JB and Specenier P: Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 21(Suppl 7): vii252–vii261. 2010. View Article : Google Scholar : PubMed/NCBI
26	Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 25:2171–2177. 2007. View Article : Google Scholar : PubMed/NCBI
27	Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, et al: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 3:99ra862011. View Article : Google Scholar : PubMed/NCBI
28	Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, et al: Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 130:2445–2454. 2012. View Article : Google Scholar
29	Hartmann S, Neckel N, Seher A, Mutzbauer G, Brands RC, Linz C, Kübler A and Müller-Richter UD: Erlotinib and gefitinib responsiveness in head and neck cancer cell lines - a comparing analysis with cetuximab. Clin Oral Investig. Aug 23–2015.Epub ahead of print. View Article : Google Scholar